IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma

PURPOSE: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults with a median survival of 15–20 months. Numerous approaches and novel therapeutics for treating GBM have been investigated in the setting of phase III clinical trials, including a recent analysis of the immune checkpoin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ladomersky, Erik, Zhai, Lijie, Lenzen, Alicia, Lauing, Kristen L., Qian, Jun, Scholtens, Denise M., Gritsina, Galina, Sun, Xuebing, Liu, Ye, Yu, Fenglong, Gong, Wenfeng, Liu, Yong, Jiang, Beibei, Tang, Tristin, Patel, Ricky, Platanias, Leonidas C., James, C. David, Stupp, Roger, Lukas, Rimas V., Binder, David C., Wainwright, Derek A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984675/
https://ncbi.nlm.nih.gov/pubmed/29500275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3573
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados